{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:27:28Z","timestamp":1779236848874,"version":"3.51.4"},"reference-count":27,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic VEGA","award":["1\/0024\/21"],"award-info":[{"award-number":["1\/0024\/21"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>The beneficial effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in hypertensive patients with peripheral arterial disease (PAD) depends on long-term persistence. The aims of our study were to analyse gender differences in non-persistence with ACEIs\/ARBs, and to identify the characteristics associated with the likelihood of non-persistence. Our study cohort included 7080 hypertensive patients (4005 women and 3075 men) aged \u226565 years, treated with ACEIs\/ARBs, in whom PAD was diagnosed between 1 January and 31 December 2012. Non-persistence was identified according to a treatment gap of 6 months without ACEI\/ARB prescriptions. The characteristics associated with non-persistence were identified using the Cox regression model. At the end of the 5-year follow-up, 23.2% of the whole study cohort, 22.3% of men, and 23.9% of women were non-persistent with ACEIs\/ARBs, with no significant gender differences in persistence. While a number of characteristics were associated with non-persistence, only three characteristics had consistent, statistically significant associations in both genders: being a new ACEI\/ARB user increased the likelihood of non-persistence, and general practitioner as index prescriber and increasing the overall number of medications decreased the likelihood of non-persistence. Information on the differences in characteristics that are associated with non-persistence between genders may help to better identify patients for whom special attention should be paid to improve their persistence.<\/jats:p>","DOI":"10.3390\/biomedicines10071479","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T21:31:06Z","timestamp":1655933466000},"page":"1479","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gender Differences in Non-Persistence with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among Older Hypertensive Patients with Peripheral Arterial Disease"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7672-1574","authenticated-orcid":false,"given":"Martin","family":"Wawruch","sequence":"first","affiliation":[{"name":"Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, 811 08 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Murin","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine, Faculty of Medicine, Comenius University, 813 69 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0023-4574","authenticated-orcid":false,"given":"Tomas","family":"Tesar","sequence":"additional","affiliation":[{"name":"Department of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University, 832 32 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Paduchova","sequence":"additional","affiliation":[{"name":"Department of Angiology, Health Centre, 917 01 Trnava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Petrova","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, 811 08 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denisa","family":"Celovska","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine, Faculty of Medicine, Comenius University, 813 69 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Havelkova","sequence":"additional","affiliation":[{"name":"General Health Insurance Company, 851 04 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4599-1971","authenticated-orcid":false,"given":"Michal","family":"Trnka","sequence":"additional","affiliation":[{"name":"Institute of Medical Physics, Biophysics, Informatics and Telemedicine, Faculty of Medicine, Comenius University, 813 72 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0030-0228","authenticated-orcid":false,"given":"Lucia","family":"Masarykova","sequence":"additional","affiliation":[{"name":"Department of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University, 832 32 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5419-8938","authenticated-orcid":false,"given":"Sofa D.","family":"Alfian","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor 45363, Indonesia"},{"name":"Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Jatinangor 45363, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6555-7833","authenticated-orcid":false,"given":"Emma","family":"Aarnio","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Eastern Finland, 70211 Kuopio, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.tvir.2016.04.001","article-title":"Epidemiology of Peripheral Arterial Disease and Critical Limb Ischemia","volume":"19","author":"Dua","year":"2016","journal-title":"Tech. Vasc. Interv. Radiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1080\/14656566.2020.1774556","article-title":"Current and emerging drug treatment strategies for peripheral arterial disease","volume":"21","author":"Essa","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_3","unstructured":"GBD 2015 Mortality and Causes of Death Collaborators (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388, 1459\u20131544."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1177\/0003319715626849","article-title":"Low Rates of Revascularization and High In-Hospital Mortality in Patients with Ischemic Lower Limb Amputation: Morbidity and Mortality of Ischemic Amputation","volume":"67","author":"Malyar","year":"2016","journal-title":"Angiology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.atherosclerosis.2018.05.033","article-title":"Update on peripheral artery disease: Epidemiology and evidence-based facts","volume":"275","author":"Shu","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_6","first-page":"362","article-title":"Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment","volume":"99","author":"Firnhaber","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.2018.5422","article-title":"Antithrombotic Therapy for Peripheral Artery Disease in 2018","volume":"319","author":"Hess","year":"2018","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: The European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_9","first-page":"e726","article-title":"2016 AHA\/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gornik","year":"2017","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M18-0543","article-title":"ESPACOMP Medication Adherence Reporting Guideline (EMERGE)","volume":"169","author":"Zullig","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"ABC Project Team. A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J. Hypertens."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3346\/jkms.2015.30.12.1800","article-title":"Persistence with Antihypertensive Medications in Uncomplicated Treatment-Na\u00efve Patients: Effects of Initial Therapeutic Classes","volume":"30","author":"Ah","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e4908","DOI":"10.1097\/MD.0000000000004908","article-title":"Persistence to antihypertensive drug classes: A cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD)","volume":"95","author":"Kahan","year":"2016","journal-title":"Medicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/pds.1156","article-title":"Differences in antihypertensive drug persistence associated with drug class and gender: A PHARMO study","volume":"14","author":"Erkens","year":"2005","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_16","unstructured":"(1992). ICD-10th International Statistical Classification of Diseases and Related Health Problems 10th Revision, WHO."},{"key":"ref_17","unstructured":"(2018). Guidelines for ATC classification and DDD assignment 2018, WHO Collaborating Centre for Drug Statistics Methodology."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Newman, S.C. (2001). Biostatistical Methods in Epidemiology, Wiley.","DOI":"10.1002\/0471272612"},{"key":"ref_19","first-page":"609","article-title":"Compliance, persistence, and switching patterns for ACE inhibitors and ARBs","volume":"17","author":"Vegter","year":"2011","journal-title":"Am. J. Manag. Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cjca.2014.03.017","article-title":"Hypertension Outcome and Surveillance Team. Antihypertensive drug prescribing and persistence among new elderly users: Implications for persistence improvement interventions","volume":"30","author":"Tu","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00228-013-1555-z","article-title":"Persistence to antihypertensive drug treatment in Swedish primary healthcare","volume":"69","author":"Kahan","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/jwh.2011.2876","article-title":"Gender differences in utilization of preventive care services in the United States","volume":"21","author":"Vaidya","year":"2012","journal-title":"J. Womens Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1345\/aph.1E548","article-title":"Persistence with treatment in newly treated middle-aged patients with essential hypertension","volume":"39","author":"Perreault","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1524-4733.2007.00247.x","article-title":"Comparison of persistence rates with angiotensin-converting enzyme inhibitors used in secondary and primary prevention of cardiovascular disease","volume":"10","author":"Gogovor","year":"2007","journal-title":"Value Health"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/01.hjh.0000226211.95936.f5","article-title":"Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice","volume":"24","author":"Burke","year":"2006","journal-title":"J. Hypertens."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/10641963.2015.1116548","article-title":"Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study","volume":"38","author":"Ah","year":"2016","journal-title":"Clin. Exp. Hypertens."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/01.hjh.0000187261.40190.2e","article-title":"Rate and determinants of 10-year persistence with antihypertensive drugs","volume":"23","author":"Klungel","year":"2005","journal-title":"J. Hypertens."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1479\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:37:48Z","timestamp":1760139468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071479"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071479","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}